Insulin resistance in patients with psoriasis
Keywords:psoriasis, insulin resistance, obesity, comorbidity, genetic polymorphism
Psoriasis is a chronic systemic inflammatory disease accompanied by an activation of skin dendritic cells with accumulation in the inflammatory foci of interleukin-23 and activated Th-1 lymphocytes (Th-17, Th-22). In recent years, there has been a large number of evidence linking psoriasis with other inflammatory diseases, including obesity, diabetes mellitus, atherosclerosis, hypertension, nonalcoholic fatty liver disease, polycystic ovary syndrome, benign prostatic hyperplasia, etc. All of these conditions are associated with systemic inflammation and insulin resistance induced by it. Psoriasis is the most common chronic dermatosis and affects 1–2 % of the population in developed countries. Psoriasis as a chronic immune-mediated inflammatory skin disease is often associated with metabolic syndrome and its components such as obesity, hypertension, insulin resistance and dyslipidemia. The risk of developing metabolic syndrome in patients with psoriasis is 40 % higher than in the general population. Psoriasis and metabolic syndrome share some pathogenic mechanisms such as chronic low-grade systemic inflammation and an increased level of pro-inflammatory cytokines. Systemic inflammation causes obesity, cardiovascular diseases, diabetes mellitus type 2. These conditions increase the risk of mortality among patients with psoriasis. There is a positive correlation between the severity of psoriasis and metabolic syndrome, which is manifested by a severe rash, reduction of the remission and higher risk of psoriatic arthritis development. The carriers of the risk allele of FTO gene are characterized by a more severe psoriasis, the presence of psoriatic arthritis and increased body mass index. A review of the literature focuses on the relationship between insulin resistance and the pathogenesis of psoriasis.
Łebkowska A, Krentowska A, Adamska A, et al. Type B insulin resistance syndrome associated with connective tissue disease and psoriasis. Endocrinol Diabetes Metab Case Rep. 2020 Aug 4;2020:20-0027. doi: 10.1530/EDM-20-0027.
Wen S, Liu C, Li Y, Pan J, Nguyen T, Zhou L. Psoriasis Exacerbates the State of Insulin Resistance in Patients with Type 2 Diabetes. Diabetes Metab Syndr Obes. 2021 May 26;14:2389-2397. doi: 10.2147/DMSO.S312420.
Polic MV, Miskulin M, Smolic M, et al. Psoriasis Severity – A Risk Factor of Insulin Resistance Independent of Metabolic Syndrome. Int J Environ Res Public Health. 2018;15(7):1486. doi: 10.3390/ijerph15071486.
Chan WMM, Yew YW, Theng TSC, Liew CF, Oon HH. Prevalence of metabolic syndrome in patients with psoriasis: a cross-sectional study in Singapore. Singapore Med J. 2020 Apr;61(4):194-199. doi: 10.11622/smedj.2019152.
Caroppo F, Galderisi A, Ventura L, Belloni Fortina A. Metabolic syndrome and insulin resistance in pre-pubertal children with psoriasis. Eur J Pediatr. 2021;180(6):1739-1745. doi: 10.1007/s00431-020-03924-w.
Bulur I, Erdogan HK, Kocatürk E, et al. The role of irisin in the relationship between psoriasis and insulin resistance. G Ital Dermatol Venereol. 2018;153(4):477-482. doi: 10.23736/S0392-0488.16.05413-4.
Choudhary S, Pradhan D, Pandey A, et al. The Association of Metabolic Syndrome and Psoriasis: A Systematic Review and Meta-Analysis of Observational Study. Endocr Metab Immune Disord Drug Targets. 2020;20(5):703-717. doi: 10.2174/1871530319666191008170409.
Paroutoglou K, Papadavid E, Christodoulatos GS, Dalamaga M. Deciphering the Association Between Psoriasis and Obesity: Current Evidence and Treatment Considerations. Curr Obes Rep. 2020 Sep;9(3):165-178. doi: 10.1007/s13679-020-00380-3.
Li B, Xi P, Wang Z, Han X, Xu Y, Zhang Y, Miao J. PI3K/Akt/mTOR signaling pathway participates in Streptococcus uberis-induced inflammation in mammary epithelial cells in concert with the classical TLRs/NF-ĸB pathway. Vet Microbiol. 2018 Dec;227:103-111. doi: 10.1016/j.vetmic.2018.10.031.
Singh S, Bhansali A. Randomized Placebo Control Study of Metformin in Psoriasis Patients with Metabolic Syndrome (Systemic Treatment Cohort). Indian J Endocrinol Metab. 2017 Jul-Aug;21(4):581-587. doi: 10.4103/ijem.IJEM_46_17.
Chang G, Wang J, Song J, Zhang Z, Zhang L. Efficacy and safety of pioglitazone for treatment of plaque psoriasis: a systematic review and meta-analysis of randomized controlled trials. J Dermatolog Treat. 2020 Nov;31(7):680-686. doi: 10.1080/09546634.2019.1610552.
Hafez VG, Bosseila M, Abdel Halim MR, Shaker OG, Kamal M, Kareem HS. Clinical effects of "pioglitazone", an insulin sensitizing drug, on psoriasis vulgaris and its co-morbidities, a double blinded randomized controlled trialx1. J Dermatolog Treat. 2015 Jun;26(3):208-14. doi: 10.3109/09546634.2014.932324.
Armstrong AW, Harskamp CT, Armstrong EJ. Psoriasis and metabolic syndrome: a systematic review and meta-analysis of observational studies. J Am Acad Dermatol. 2013 Apr;68(4):654-662. doi: 10.1016/j.jaad.2012.08.015.
Snekvik I, Nilsen TIL, Romundstad PR, Saunes M. Metabolic syndrome and risk of incident psoriasis: prospective data from the HUNT Study, Norway. Br J Dermatol. 2019 Jan;180(1):94-99. doi: 10.1111/bjd.16885.
Polic MV, Miskulin M, Smolic M, Kralik K, Miskulin I, Berkovic MC, Curcic IB. Psoriasis Severity-A Risk Factor of Insulin Resistance Independent of Metabolic Syndrome. Int J Environ Res Public Health. 2018 Jul 13;15(7):1486. doi: 10.3390/ijerph15071486.
Souza CS, de Castro CCS, Carneiro FRO, et al. Metabolic syndrome and psoriatic arthritis among patients with psoriasis vulgaris: Quality of life and prevalence. J Dermatol. 2019 Jan;46(1):3-10. doi: 10.1111/1346-8138.14706.
Novelli L, Lubrano E, Venerito V, et al. Extra-Articular Manifestations and Comorbidities in Psoriatic Disease: A Journey Into the Immunologic Crosstalk. Front Med (Lausanne). 2021 Sep 23;8:737079. doi: 10.3389/fmed.2021.737079.
Owczarczyk-Saczonek A, Purzycka-Bohdan D, Nedoszytko B, et al. Pathogenesis of psoriasis in the "omic" era. Part III. Metabolic disorders, metabolomics, nutrigenomics in psoriasis. Postepy Dermatol Alergol. 2020 Aug;37(4):452-467. doi: 10.5114/ada.2020.98284.
Johnson JA, Ma C, Kanada KN, Armstrong AW. Diet and nutrition in psoriasis: analysis of the National Health and Nutrition Examination Survey (NHANES) in the United States. J Eur Acad Dermatol Venereol. 2014 Mar;28(3):327-32. doi: 10.1111/jdv.12105.
Chang JY, Park JH, Park SE, Shon J, Park YJ. The Fat Mass- and Obesity-Associated (FTO) Gene to Obesity: Lessons from Mouse Models. Obesity (Silver Spring). 2018 Nov;26(11):1674-1686. doi: 10.1002/oby.22301.
Castellini G, Franzago M, Bagnoli S, et al. Fat mass and obesity-associated gene (FTO) is associated to eating disorders susceptibility and moderates the expression of psychopathological traits. PLoS One. 2017 Mar 10;12(3):e0173560. doi: 10.1371/journal.pone.0173560.
Ford AR, Siegel M, Bagel J, et al. Dietary Recommendations for Adults With Psoriasis or Psoriatic Arthritis From the Medical Board of the National Psoriasis Foundation: A Systematic Review. JAMA Dermatol. 2018 Aug 1;154(8):934-950. doi: 10.1001/jamadermatol.2018.1412.
How to Cite
Copyright (c) 2021 I.V. Pankiv
This work is licensed under a Creative Commons Attribution 4.0 International License.